Division of Hematology and Oncology

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Biltibo receives career development award to support hematology research

Vanderbilt’s Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.

Black patients with cancer face worse COVID outcomes: study

Vanderbilt researchers have found that Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients.

Berlin named interim leader of Hematology and Oncology

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt’s Division of Hematology and Oncology in the Department of Medicine.

P. Brent Ferrell, MD, is part of a multidisciplinary team studying new approaches to understand and treat cancer.

Ferrell lands Mark Foundation for Cancer Research award

Vanderbilt’s Brent Ferrell, MD, is one of the recipients a 2022 Endeavor Award from the The Mark Foundation for Cancer Research.

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease

1 2 3 4 5 6 13